Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
2025 Q4 -tulosraportti

Vain PDF

14 päivää sitten

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 2 min sitten
    ·
    2 min sitten
    ·
    We should probably have a joint Christmas party or something eventually 😅🍻
    Alle minuutti sitten
    Alle minuutti sitten
    If you do it in Oslo I will definitely come 💯 🫶
  • 11 min sitten
    ·
    11 min sitten
    ·
    Today's news briefly summarized: Circio will now test the delivery of circVec using peptides. This will happen in collaboration with the University of Santiago under their "TraffikGene" project. Previously, circVec has been tested with AAV (virus-based delivery system), and has an ongoing LNP collaboration with Acuitas in the CAR-T study. LNP is like a microscopic fat bubble that can transport genetic material to the cells. We don't have data from this yet. I personally find LNP very interesting. With today's news, we thus learn that Circio is exploring yet another delivery platform for circVec, and it doesn't stop there. With the help of "peptide carriers", they will also explore delivery to new tissues they haven't tested before, possibly on tissues that the other two delivery platforms don't target as well. In the long term, this could develop into new disease models and even more indications. All in all, today's news strengthens the fact that circVec is a platform technology that can potentially be used for multiple purposes with the help of various tools. The CEO's goal at the start of the year was to secure more collaboration agreements and research fields, and they have truly delivered here. Today's news is the third collaboration agreement in a short time and actively expands circVec's ecosystem. If circVec works equally well across AAV, LNP and peptide carriers, then this strengthens the platform immensely.
    6 min sitten
    ·
    6 min sitten
    ·
    The value of circio as an acquisition candidate has strengthened significantly.
    2 min sitten
    ·
    2 min sitten
    ·
    We need data first. We only have data on AAV so far. But Circio is doing an incredibly good job of expanding their platform and keeping the wind in their sails. This is naturally being noticed in the industry!
  • 16 min sitten
    ·
    16 min sitten
    ·
    🌞BUY THE DIP🌞
    4 min sitten
    ·
    4 min sitten
    ·
    If only I had more cash 😭…..
  • 31 min sitten
    ·
    31 min sitten
    ·
    New day - New opportunities - Good News , It can't get any better ✅🥳Good luck!
    16 min sitten
    ·
    16 min sitten
    ·
    So much great news lately, it's unbelievable! 🥳🥳🥳🥳🥳
  • 1 t sitten
    ·
    1 t sitten
    ·
    Second day with good news in a row, so then it will probably be a blood-red day... figure that out if you can 🫣
    44 min sitten
    ·
    44 min sitten
    ·
    It seems that one is accelerating strongly after the emission, as collaboration agreements and news are coming almost daily. The 250 mill. have really gotten legs to walk on. Acquisition or licensing, whatever it ends up being in the end, now seems to be happening much faster than 24 months into the future. Is Big Pharma willing to wait until autumn before the first bid comes?
    1 min sitten · Muokattu
    ·
    1 min sitten · Muokattu
    ·
    I'll bet a whole foamy Bavarian beer that Big Pharma doesn't know their place. And it wouldn't surprise me either if Circio is not at all interested in being acquired - because here, one clearly knows its own worth. This company is a future behemoth. And just an independent AI-free thought: how many have considered whether the massive share issues, among other things, have aimed to reject forced acquisitions from foreign usurpers? Internally at Circio, one could actually have a desire to grow and exist free and independent. That perspective will probably disappoint many investors. Personally, I would prefer an independent Circio, but if they sell themselves to the highest bidder, then that's their own choice.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

14 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 2 min sitten
    ·
    2 min sitten
    ·
    We should probably have a joint Christmas party or something eventually 😅🍻
    Alle minuutti sitten
    Alle minuutti sitten
    If you do it in Oslo I will definitely come 💯 🫶
  • 11 min sitten
    ·
    11 min sitten
    ·
    Today's news briefly summarized: Circio will now test the delivery of circVec using peptides. This will happen in collaboration with the University of Santiago under their "TraffikGene" project. Previously, circVec has been tested with AAV (virus-based delivery system), and has an ongoing LNP collaboration with Acuitas in the CAR-T study. LNP is like a microscopic fat bubble that can transport genetic material to the cells. We don't have data from this yet. I personally find LNP very interesting. With today's news, we thus learn that Circio is exploring yet another delivery platform for circVec, and it doesn't stop there. With the help of "peptide carriers", they will also explore delivery to new tissues they haven't tested before, possibly on tissues that the other two delivery platforms don't target as well. In the long term, this could develop into new disease models and even more indications. All in all, today's news strengthens the fact that circVec is a platform technology that can potentially be used for multiple purposes with the help of various tools. The CEO's goal at the start of the year was to secure more collaboration agreements and research fields, and they have truly delivered here. Today's news is the third collaboration agreement in a short time and actively expands circVec's ecosystem. If circVec works equally well across AAV, LNP and peptide carriers, then this strengthens the platform immensely.
    6 min sitten
    ·
    6 min sitten
    ·
    The value of circio as an acquisition candidate has strengthened significantly.
    2 min sitten
    ·
    2 min sitten
    ·
    We need data first. We only have data on AAV so far. But Circio is doing an incredibly good job of expanding their platform and keeping the wind in their sails. This is naturally being noticed in the industry!
  • 16 min sitten
    ·
    16 min sitten
    ·
    🌞BUY THE DIP🌞
    4 min sitten
    ·
    4 min sitten
    ·
    If only I had more cash 😭…..
  • 31 min sitten
    ·
    31 min sitten
    ·
    New day - New opportunities - Good News , It can't get any better ✅🥳Good luck!
    16 min sitten
    ·
    16 min sitten
    ·
    So much great news lately, it's unbelievable! 🥳🥳🥳🥳🥳
  • 1 t sitten
    ·
    1 t sitten
    ·
    Second day with good news in a row, so then it will probably be a blood-red day... figure that out if you can 🫣
    44 min sitten
    ·
    44 min sitten
    ·
    It seems that one is accelerating strongly after the emission, as collaboration agreements and news are coming almost daily. The 250 mill. have really gotten legs to walk on. Acquisition or licensing, whatever it ends up being in the end, now seems to be happening much faster than 24 months into the future. Is Big Pharma willing to wait until autumn before the first bid comes?
    1 min sitten · Muokattu
    ·
    1 min sitten · Muokattu
    ·
    I'll bet a whole foamy Bavarian beer that Big Pharma doesn't know their place. And it wouldn't surprise me either if Circio is not at all interested in being acquired - because here, one clearly knows its own worth. This company is a future behemoth. And just an independent AI-free thought: how many have considered whether the massive share issues, among other things, have aimed to reject forced acquisitions from foreign usurpers? Internally at Circio, one could actually have a desire to grow and exist free and independent. That perspective will probably disappoint many investors. Personally, I would prefer an independent Circio, but if they sell themselves to the highest bidder, then that's their own choice.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

14 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 2 min sitten
    ·
    2 min sitten
    ·
    We should probably have a joint Christmas party or something eventually 😅🍻
    Alle minuutti sitten
    Alle minuutti sitten
    If you do it in Oslo I will definitely come 💯 🫶
  • 11 min sitten
    ·
    11 min sitten
    ·
    Today's news briefly summarized: Circio will now test the delivery of circVec using peptides. This will happen in collaboration with the University of Santiago under their "TraffikGene" project. Previously, circVec has been tested with AAV (virus-based delivery system), and has an ongoing LNP collaboration with Acuitas in the CAR-T study. LNP is like a microscopic fat bubble that can transport genetic material to the cells. We don't have data from this yet. I personally find LNP very interesting. With today's news, we thus learn that Circio is exploring yet another delivery platform for circVec, and it doesn't stop there. With the help of "peptide carriers", they will also explore delivery to new tissues they haven't tested before, possibly on tissues that the other two delivery platforms don't target as well. In the long term, this could develop into new disease models and even more indications. All in all, today's news strengthens the fact that circVec is a platform technology that can potentially be used for multiple purposes with the help of various tools. The CEO's goal at the start of the year was to secure more collaboration agreements and research fields, and they have truly delivered here. Today's news is the third collaboration agreement in a short time and actively expands circVec's ecosystem. If circVec works equally well across AAV, LNP and peptide carriers, then this strengthens the platform immensely.
    6 min sitten
    ·
    6 min sitten
    ·
    The value of circio as an acquisition candidate has strengthened significantly.
    2 min sitten
    ·
    2 min sitten
    ·
    We need data first. We only have data on AAV so far. But Circio is doing an incredibly good job of expanding their platform and keeping the wind in their sails. This is naturally being noticed in the industry!
  • 16 min sitten
    ·
    16 min sitten
    ·
    🌞BUY THE DIP🌞
    4 min sitten
    ·
    4 min sitten
    ·
    If only I had more cash 😭…..
  • 31 min sitten
    ·
    31 min sitten
    ·
    New day - New opportunities - Good News , It can't get any better ✅🥳Good luck!
    16 min sitten
    ·
    16 min sitten
    ·
    So much great news lately, it's unbelievable! 🥳🥳🥳🥳🥳
  • 1 t sitten
    ·
    1 t sitten
    ·
    Second day with good news in a row, so then it will probably be a blood-red day... figure that out if you can 🫣
    44 min sitten
    ·
    44 min sitten
    ·
    It seems that one is accelerating strongly after the emission, as collaboration agreements and news are coming almost daily. The 250 mill. have really gotten legs to walk on. Acquisition or licensing, whatever it ends up being in the end, now seems to be happening much faster than 24 months into the future. Is Big Pharma willing to wait until autumn before the first bid comes?
    1 min sitten · Muokattu
    ·
    1 min sitten · Muokattu
    ·
    I'll bet a whole foamy Bavarian beer that Big Pharma doesn't know their place. And it wouldn't surprise me either if Circio is not at all interested in being acquired - because here, one clearly knows its own worth. This company is a future behemoth. And just an independent AI-free thought: how many have considered whether the massive share issues, among other things, have aimed to reject forced acquisitions from foreign usurpers? Internally at Circio, one could actually have a desire to grow and exist free and independent. That perspective will probably disappoint many investors. Personally, I would prefer an independent Circio, but if they sell themselves to the highest bidder, then that's their own choice.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt
© 2026 Nordnet Bank AB.
Nordnet | Alvar Aallon katu 5 C, 3. krs | FI-00100 Helsinki